Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ascendis Pharma AS (NASDAQ: ASND).

Full DD Report for ASND

You must become a subscriber to view this report.


Recent News from (NASDAQ: ASND)

Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
COPENHAGEN, Denmark, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced upcoming presentations related to its technology platf...
Source: GlobeNewswire
Date: September, 06 2018 16:02
Ascendis Pharma (ASND) CEO Jan Mikkelsen on Q2 2018 Results - Earnings Call Transcript
Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call August 30, 2018 16:30 ET Executives Scott Smith - Chief Financial Officer Jan Mikkelsen - President and Chief Executive Officer Jonathan Leff - Chief Medical Officer Analysts Jessica Fye - JPMorgan Michelle Gilson - ...
Source: SeekingAlpha
Date: August, 29 2018 21:42
Ascendis Pharma  reports Q2 results
Ascendis Pharma  (NASDAQ: ASND ): Q2 GAAP EPS of -€0.55. More news on: Ascendis Pharma, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 16:10
Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results
- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon ™ technology in a new therapeutic area - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ascendis Phar...
Source: GlobeNewswire
Date: August, 29 2018 16:01
Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29
COPENHAGEN, Denmark, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webca...
Source: GlobeNewswire
Date: August, 15 2018 16:15
Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference
COPENHAGEN, Denmark, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will participate in an upcoming investor confe...
Source: GlobeNewswire
Date: August, 02 2018 07:00
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced a poster presentation on its TransCon technology at the annual m...
Source: GlobeNewswire
Date: July, 23 2018 16:44
Entera Bio Aims Lower For Improved IPO Terms
Quick Take Entera Bio ( ENTX ) intends to raise $12 million in an IPO from the sale of its common stock and warrants. The firm is developing a pipeline of drugs utilizing its proprietary large molecule oral drug delivery modalities. ENTX has significantly improved the terms of its IP...
Source: SeekingAlpha
Date: June, 28 2018 16:16
Institutional Top Ideas: Cormorant Asset Management
In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t...
Source: SeekingAlpha
Date: June, 16 2018 18:41
Institutional Top Ideas: EcoR1 Capital
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw...
Source: SeekingAlpha
Date: June, 12 2018 02:08

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0867.7465.1468.5765.00143,872
2018-05-1767.3566.9268.3866.710665,018
2017-06-2023.4022.8223.6421.95140,505
2017-06-1923.7324.0525.1223.05822,443
2017-06-1623.4224.0024.3922.9554,135

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-114,14610,63938.9698Short
2018-12-103,17446,5476.8189Cover
2018-12-078,06417,16846.9711Short
2018-12-067,47219,41338.4897Short
2018-12-0411,69132,33736.1536Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ASND.


About Ascendis Pharma AS (NASDAQ: ASND)

Logo for Ascendis Pharma AS (NASDAQ: ASND)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ASND)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 03 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 28 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 28 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: February, 23 2018

       

       


      Daily Technical Chart for (NASDAQ: ASND)

      Daily Technical Chart for (NASDAQ: ASND)


      Stay tuned for daily updates and more on (NASDAQ: ASND)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ASND)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ASND is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ASND and does not buy, sell, or trade any shares of ASND. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/